Merendino Lauren
Chief Commercial Officer
Merendino Lauren has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Apr 23, 2026.
On the most recent filing, Merendino Lauren is listed as Chief Commercial Officer at Day One Biopharmaceuticals, Inc. Inside the rolling window, Merendino Lauren reported no open-market purchases and 2 open-market sales totaling $101K in DAWN. The largest disclosed transaction in the window is a sale of 5,814 DAWN shares on Feb 17, 2026, worth $67K.
Companies traded
Other insiders at DAWN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$101K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Merendino Lauren made?
Merendino Lauren has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Merendino Lauren trade?
Merendino Lauren has filed SEC Form 4 disclosures for 1 company, including DAWN.
When was Merendino Lauren's most recent SEC Form 4 filing?
Merendino Lauren's most recent SEC Form 4 filing on Tracefour is dated Apr 23, 2026.
What is Merendino Lauren's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Merendino Lauren is listed as Chief Commercial Officer.
What is Merendino Lauren's total buy and sell value in the current window?
Inside the rolling retention window, Merendino Lauren bought $0 and sold $101K based on SEC Form 4 filings.
What was Merendino Lauren's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,814 DAWN shares on 2026-02-17, worth $67K, per SEC Form 4 filings.